NitroMed, Boston Scientific end research program on nitric oxide-enhancing technology

By E. Janene Geiss

Philadelphia, Dec. 29 - NitroMed said Thursday that its research program with Boston Scientific, under which NitroMed's nitric oxide-enhancing technology was being studied in connection with restenosis in balloon angioplasty, will end Dec. 31.

NitroMed said it intends to continue to explore the use of its nitric oxide-enhancing technology in medical devices.

NitroMed is a Lexington, Mass., research-based pharmaceutical company and the maker of BiDil (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine that may be prescribed in the United States for the treatment of heart failure in self-identified black patients.

In this population, BiDil is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil was approved by the Food and Drug Administration, primarily on the basis of efficacy data from the company's landmark A-HeFT (African American Heart Failure Trial) clinical trial, and is marketed by NitroMed through a nationwide, dedicated sales force.

The company said it is committed to development of new drugs and safer, more effective versions of existing drugs to treat underserved patients. NitroMed's efforts are focused on expanding its cardiovascular franchise, officials said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.